LifeTech Scientific’s Aortic Arch Stent Graft System Gains China NMPA Approval

LifeTech Scientific Corporation ( (HK:1302) ) just unveiled an update.

LifeTech Scientific Corporation has announced the official registration approval from the China National Medical Products Administration for its Aortic Arch Stent Graft System, a pioneering product aimed at aortic arch branch reconstruction using the fenestration technique. This approval marks a significant milestone in the company’s product portfolio, enhancing its position in the peripheral vascular intervention field. The system, which includes the Ankura™ Plus and CSkirt™ components, demonstrated high success rates and safety in clinical studies, and is expected to provide a comprehensive and effective solution for aortic dissection lesions. The launch is anticipated to drive further development and commercialization of innovative medical devices, benefiting a wide range of patients.

More about LifeTech Scientific Corporation

LifeTech Scientific Corporation operates in the medical devices industry, focusing on peripheral vascular intervention solutions. The company develops innovative products for endovascular repair, with a particular emphasis on aortic dissection treatments.

Average Trading Volume: 26,419,412

Technical Sentiment Signal: Sell

Current Market Cap: HK$6.69B

Find detailed analytics on 1302 stock on TipRanks’ Stock Analysis page.